Visualisation of a Digital Care Pathway.

Sponsor
Jessa Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05226182
Collaborator
Wit-Gele Kruis Limburg (Other), KLAV (Other), Ferm Thuiszorg (Other), I-mens (Other), Vlaams Patiëntenplatform (Other), Wit-Gele Kruis Vlaanderen (Other), POM Limburg (Other)
45
1
2
8.9
5

Study Details

Study Description

Brief Summary

As part of the EFRO (Europees Fonds Regionale Ontwikkeling) 1302 project "Digital Care Support in Practice with Limburg as a Stepping Stone for Flanders", this study aims to evaluate the concept and added value of visualising a personal digital care pathway for patients with type 2 diabetes. Firstly, this chronological visualisation of data strives to improve patient experience and empowerment by offering educational articles and personal medical data relevant to their care path in one place. This way, patients will have more insight in the pathogenesis, treatments, complications and goals, allowing the patients to optimize their selfcare and become confident in dealing with their chronic condition. From time to time, patients will also be asked to complete questionnaires concerning their experiences (PREM) to aid healthcare professionals in personalizing treatment goals. Secondly, the healthcare providers and caregivers surrounding the patient will also have access to the same data, allowing for a more personal approach as well as means to communicate with other members of the care team.

Condition or Disease Intervention/Treatment Phase
  • Other: visualisation of a digital care path
N/A

Detailed Description

Good quality of care requires a multidisciplinary approach, especially with chronic illnesses. Therefore, all members of the care team should be adequately informed and communicate well with each other. Additionally, patients should have a key role in their treatment plan. To successfully optimize self care, patients have to be well-informed about pathogenesis, treatments and complications so that expectations are realistic and attainable goals can be set. Currently, access to this relevant data is fragmented and often unavailable.

The newly developed application creates a central platform where all relevant data, educational material, medication scheme... are available for both the patient and healthcare professionals. The targeted study population are patients with type 2 diabetes who will be recruited by their general practitioner (GP) over a period of 3 months. When patients are interested in partaking, they will be contacted by a healthcare professional who will function as a Single Point of Contact (SPOC) for the patient during the entirety of the study with a maximum duration of 6 months. The SPOC helps with the start up of the application, collects administrative data and contacts the participants at regular intervals to help with difficulties in using the application. Furthermore, the SPOC will administer a questionnaire determining patient involvement and experience at the start and end of the study, as well as conduct an in-depth interview when the study is completed. Throughout the study, other questionnaires will be digitally available for the patient as part of the care path. These patient reported outcome and experience measures (PROM/PREM) will support healthcare professionals in providing a more integral care.

Consequently, involved healthcare professionals will also be contacted, informed and asked to complete a questionnaire once healthcare professionals agree to participate in the study. This questionnaire will focus on the information and communication needs between members of the care team and will also be repeated at the end, followed by an in-depth interview.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
45 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
The patient population in this pilot study consists of two cohorts. All inclusions start from the GP, based on well-defined inclusion criteria. The reason for working with two parallel cohorts is based on the premise that different patient characteristics will confound the results and provide a distorted conclusion if not separated. One group is anticipated to consist of patients capable of using the application independently, while the other group is expected to have patients that will likely be more dependent on others for help with digital applications. This discrepancy could impact the usability and evaluation of the application. Literature shows that in similar pilot studies numbers of participants can vary a lot. Taking into regard the inclusion criteria, labor intensity and limited resources of this study investigators aim to include 15-30 patients for cohort 1 and 5-15 patients for cohort 2.The patient population in this pilot study consists of two cohorts. All inclusions start from the GP, based on well-defined inclusion criteria. The reason for working with two parallel cohorts is based on the premise that different patient characteristics will confound the results and provide a distorted conclusion if not separated. One group is anticipated to consist of patients capable of using the application independently, while the other group is expected to have patients that will likely be more dependent on others for help with digital applications. This discrepancy could impact the usability and evaluation of the application. Literature shows that in similar pilot studies numbers of participants can vary a lot. Taking into regard the inclusion criteria, labor intensity and limited resources of this study investigators aim to include 15-30 patients for cohort 1 and 5-15 patients for cohort 2.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Visualisation of a Digital Care Pathway in Limburg, in Context of Digital Care Support as a Stepping Stone for Flanders.
Actual Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Feb 28, 2022
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: patients

Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale. Post measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview.

Other: visualisation of a digital care path
The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.

Experimental: healthcare professionals

Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale. Post measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview.

Other: visualisation of a digital care path
The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.

Outcome Measures

Primary Outcome Measures

  1. Change in patient empowerment and involvement [For a minimum of 12 weeks]

    Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list.

  2. Change in care team communication and sharing of data [For a minimum of 12 weeks]

    Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list.

  3. Usability and acceptance of the application in patients and healthcare professionals [For a minimum of 12 weeks]

    Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list.

Secondary Outcome Measures

  1. User characteristics of the application. [for a minimum of 12 weeks]

    Data will be collected from logs, available in the back office of the application

  2. Possible change,impact on personal clinical parameters: HbA1c [for a minimum of 12 weeks]

    HbA1c will be expressed in %

  3. Possible change,impact on personal clinical parameters: blood pressure [For a minimum of 12 weeks]

    Both systolic and diastolic blood pressure will be measured, expressed in mmHg.

  4. Possible change,impact on personal clinical parameters: glycemia [For a minimum of 12 weeks]

    Glycemia will be expressed in mg/dl.

  5. Possible change,impact on personal clinical parameters: girth [For a minimum of 12 weeks]

    Girth will be expressed in cm.

  6. Possible change,impact on personal clinical parameters: bodyweight [For a minimum of 12 weeks]

    Weight will be expressed in kg.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria for cohort 1 and 2:
  • patients with type 2 diabetes (voortraject and zorgtraject)

  • independent and mentally competent

  • digitally literate and in possession of an email address

  • mastered the Dutch language

  • able to visit the GP (no house calls)

Additional inclusion criteria for cohort 2 :
  • presence of a home nurse in the context of the Diabetes care

  • presence of a home care service

Exclusion Criteria:
  • patients type 2 Diabetes enrolled in the Diabetes convention

  • pregnant patients

  • illiterate people

  • patients living in a residential care center

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jessa Hospital Hasselt Limburg Belgium 3500

Sponsors and Collaborators

  • Jessa Hospital
  • Wit-Gele Kruis Limburg
  • KLAV
  • Ferm Thuiszorg
  • I-mens
  • Vlaams Patiëntenplatform
  • Wit-Gele Kruis Vlaanderen
  • POM Limburg

Investigators

  • Principal Investigator: Yves Breysem, Dr, Jessa Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jessa Hospital
ClinicalTrials.gov Identifier:
NCT05226182
Other Study ID Numbers:
  • 2021/036
First Posted:
Feb 7, 2022
Last Update Posted:
Feb 24, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jessa Hospital

Study Results

No Results Posted as of Feb 24, 2022